TuHURA Biosciences, Inc. (NASDAQ:HURA) has released its financial results for the first quarter ending March 31, 2025. The company's research and development expenses increased to $4.6 million from $3.6 million in the same period in 2024. General and administrative expenses also rose significantly, reaching $2.4 million compared to $1.0 million for the first quarter of 2024. As of March 31, 2025, TuHURA reported approximately 43.7 million total shares outstanding. In terms of business operations, TuHURA plans to initiate a Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma (MCC) in the second quarter of 2025. Additionally, the company has initiated a Phase 1b/2a trial of IFx-Hu2.0 for first-line Merkel cell carcinoma of unknown primary origin (MCCUP). TuHURA is also targeting to complete the acquisition of Kineta, Inc. in the second quarter of 2025 and plans to start a Phase 2 trial of Kineta's VISTA inhibiting monoclonal antibody in NPM1-mutated acute myeloid leukemia in the third quarter of 2025. The company continues to advance its development of bi-specific, bi-functional immune modulating ADCs and APCs, and plans to present non-clinical data at relevant medical meetings throughout the year.